

# Larissa M Podust

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6481049/publications.pdf>

Version: 2024-02-01

75  
papers

3,879  
citations

76326

40  
h-index

123424

61  
g-index

80  
all docs

80  
docs citations

80  
times ranked

4013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intramolecular Interactions Enhance the Potency of Gallinamide A Analogues against <i>Trypanosoma cruzi</i> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4255-4269.	6.4	9
2	Homodimerization Counteracts the Detrimental Effect of Nitrogenous Heme Ligands on the Enzymatic Activity of <i>Acanthamoeba castellanii</i> CYP51. <i>Biochemistry</i> , 2022, 61, 1363-1377.	2.5	3
3	Domain-Swap Dimerization of <i>Acanthamoeba castellanii</i> CYP51 and a Unique Mechanism of Inactivation by Isavuconazole. <i>Molecular Pharmacology</i> , 2020, 98, 770-780.	2.3	2
4	HMG-CoA Reductase Inhibitors as Drug Leads against <i>Naegleria fowleri</i> . <i>ACS Chemical Neuroscience</i> , 2020, 11, 3089-3096.	3.5	13
5	Molecular Basis of Iterative C-H Oxidation by Tam1, a Multifunctional P450 Monooxygenase from the Tirandamycin Biosynthetic Pathway. <i>ACS Catalysis</i> , 2020, 10, 13445-13454.	11.2	20
6	The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against <i>Acanthamoeba castellanii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
7	Dynamic visualization of type II peptidyl carrier protein recognition in pyoluteorin biosynthesis. <i>RSC Chemical Biology</i> , 2020, 1, 8-12.	4.1	17
8	Mechanistic Insights into Cytochrome P450 Inactivation by Azole Drugs in <i>Acanthamoeba castellanii</i> . <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
9	Exploring the molecular basis for substrate specificity in homologous macrolide biosynthetic cytochromes P450. <i>Journal of Biological Chemistry</i> , 2019, 294, 15947-15961.	3.4	8
10	Identification of Four Amoebicidal Nontoxic Compounds by a Molecular Docking Screen of <i>Naegleria fowleri</i> Sterol 7-Isomerase and Phenotypic Assays. <i>ACS Infectious Diseases</i> , 2019, 5, 2029-2038.	3.8	6
11	Short-lived neutral FMN and FAD semiquinones are transient intermediates in cryo-reduced yeast NADPH-cytochrome P450 reductase. <i>Archives of Biochemistry and Biophysics</i> , 2019, 673, 108080.	3.0	0
12	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1H-pyrrolyl)(phenyl)methyl-1H-imidazole Derivatives as Antiprotozoal Agents. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1330-1347.	6.4	26
13	Regulatory mechanisms of the cholesterol catabolism repressor KstR in <i>Mycobacterium tuberculosis</i> . <i>FASEB Journal</i> , 2019, 33, 458.2.	0.5	0
14	Enzymatic chokepoints and synergistic drug targets in the sterol biosynthesis pathway of <i>Naegleria fowleri</i> . <i>PLoS Pathogens</i> , 2018, 14, e1007245.	4.7	33
15	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 53-60.	5.5	19
16	Comparative Analysis of Bacterial Cytochromes P450 Involved in the Biosynthesis of 16-Membered Ring Macrolide Antibiotics. <i>FASEB Journal</i> , 2018, 32, 529.4.	0.5	0
17	Solution Conformations and Dynamics of Substrate-Bound Cytochrome P450 MycG. <i>Biochemistry</i> , 2017, 56, 2701-2714.	2.5	19
18	Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast. <i>ACS Chemical Biology</i> , 2017, 12, 422-434.	3.4	26

#	ARTICLE	IF	CITATIONS
19	4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of <i>Trypanosoma cruzi</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006132.	3.0	24
20	Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005680.	3.0	36
21	CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006104.	3.0	45
22	Biochemical and Structural Characterization of MycCl, a Versatile P450 Biocatalyst from the Mycinamicin Biosynthetic Pathway. <i>ACS Chemical Biology</i> , 2016, 11, 2642-2654.	3.4	14
23	X-ray structures of thioredoxin and thioredoxin reductase from <i>Entamoeba histolytica</i> and prevailing hypothesis of the mechanism of Auranofin action. <i>Journal of Structural Biology</i> , 2016, 194, 180-190.	2.8	60
24	The <i>Schistosoma mansoni</i> Cytochrome P450 (CYP3050A1) Is Essential for Worm Survival and Egg Development. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004279.	3.0	37
25	Targeting Ergosterol Biosynthesis in <i>Leishmania donovani</i> : Essentiality of Sterol 14 $\alpha$ -demethylase. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003588.	3.0	90
26	Enzymatic hydroxylation of an unactivated methylene C-H bond guided by molecular dynamics simulations. <i>Nature Chemistry</i> , 2015, 7, 653-660.	13.6	100
27	Binding Mode and Potency of <i>N</i> -Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10162-10175.	6.4	22
28	<i>R</i> -Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against <i>Trypanosoma cruzi</i> . <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 434-439.	2.8	18
29	Expanding the Binding Envelope of CYP51 Inhibitors Targeting <i>Trypanosoma cruzi</i> with 4-Aminopyridyl-Based Sulfonamide Derivatives. <i>ChemBioChem</i> , 2014, 15, 1111-1120.	2.6	18
30	Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. <i>Chemical Reviews</i> , 2014, 114, 11242-11271.	47.7	74
31	4-Aminopyridyl-Based CYP51 Inhibitors as Anti- <i>Trypanosoma cruzi</i> Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6989-7005.	6.4	43
32	New Reactions and Products Resulting from Alternative Interactions between the P450 Enzyme and Redox Partners. <i>Journal of the American Chemical Society</i> , 2014, 136, 3640-3646.	13.7	68
33	Directing Group-Controlled Regioselectivity in an Enzymatic C-H Bond Oxygenation. <i>Journal of the American Chemical Society</i> , 2014, 136, 4901-4904.	13.7	75
34	A highly conserved mycobacterial cholesterol catabolic pathway. <i>Environmental Microbiology</i> , 2013, 15, 2342-2359.	3.8	54
35	Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51 as Anti-Chagas Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7651-7668.	6.4	43
36	Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. <i>Beilstein Journal of Organic Chemistry</i> , 2013, 9, 15-25.	2.2	34

#	ARTICLE	IF	CITATIONS
37	Diverse Inhibitor Chemotypes Targeting <i>Trypanosoma cruzi</i> CYP51. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1736.	3.0	54
38	Substrate Recognition by the Multifunctional Cytochrome P450 MycG in Mycinamicin Hydroxylation and Epoxidation Reactions. <i>Journal of Biological Chemistry</i> , 2012, 287, 37880-37890.	3.4	58
39	Diversity of P450 enzymes in the biosynthesis of natural products. <i>Natural Product Reports</i> , 2012, 29, 1251.	10.3	247
40	Tirandamycin biosynthesis is mediated by co-dependent oxidative enzymes. <i>Nature Chemistry</i> , 2011, 3, 628-633.	13.6	83
41	Structural control of cytochrome P450-catalyzed $\alpha$ -hydroxylation. <i>Archives of Biochemistry and Biophysics</i> , 2011, 507, 86-94.	3.0	69
42	Reverse type I inhibitor of <i>Mycobacterium tuberculosis</i> CYP125A1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 332-337.	2.2	27
43	Structure of Cytochrome P450 PimD Suggests Epoxidation of the Polyene Macrolide Pimaricin Occurs via a Hydroperoxoferric Intermediate. <i>Chemistry and Biology</i> , 2010, 17, 841-851.	6.0	49
44	<i>Mycobacterium tuberculosis</i> CYP125A1, a steroid C27 monooxygenase that detoxifies intracellularly generated cholesterol. <i>Molecular Microbiology</i> , 2010, 77, 730-742.	2.5	113
45	Structural Characterization of CYP51 from <i>Trypanosoma cruzi</i> and <i>Trypanosoma brucei</i> Bound to the Antifungal Drugs Posaconazole and Fluconazole. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e651.	3.0	106
46	A Nonazole CYP51 Inhibitor Cures Chagas Disease in a Mouse Model of Acute Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2480-2488.	3.2	56
47	Identification of Small Molecule Scaffolds for P450 Inhibitors. <i>Current Protocols in Microbiology</i> , 2010, 16, Unit17.4.	6.5	9
48	FMN Binding Site of Yeast NADPH-Cytochrome P450 Reductase Exposed at the Surface Is Highly Specific. <i>ACS Chemical Biology</i> , 2010, 5, 767-776.	3.4	8
49	<i>Trypanosoma cruzi</i> CYP51 Inhibitor Derived from a <i>Mycobacterium tuberculosis</i> Screen Hit. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e372.	3.0	60
50	Biochemical and structural characterization of CYP124: A methyl-branched lipid $\alpha$ -hydroxylase from <i>Mycobacterium tuberculosis</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20687-20692.	7.1	89
51	Interaction of <i>Mycobacterium tuberculosis</i> CYP130 with Heterocyclic Arylamines. <i>Journal of Biological Chemistry</i> , 2009, 284, 25211-25219.	3.4	34
52	Analysis of Transient and Catalytic Desosamine-binding Pockets in Cytochrome P-450 PikC from <i>Streptomyces venezuelae</i> . <i>Journal of Biological Chemistry</i> , 2009, 284, 5723-5730.	3.4	45
53	Selective oxidation of carbolide C-H bonds by an engineered macrolide P450 mono-oxygenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18463-18468.	7.1	86
54	2.3 Å... X-ray Structure of the Heme-Bound GAF Domain of Sensory Histidine Kinase DosT of <i>Mycobacterium tuberculosis</i> . <i>Biochemistry</i> , 2008, 47, 12523-12531.	2.5	71

#	ARTICLE	IF	CITATIONS
55	Mycobacterium tuberculosis CYP130. Journal of Biological Chemistry, 2008, 283, 5069-5080.	3.4	83
56	X-ray Structure of 4,4- $\epsilon^2$ -Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14 $\alpha$ -Demethylase (CYP51). Journal of Biological Chemistry, 2008, 283, 15152-15159.	3.4	34
57	Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography. Antimicrobial Agents and Chemotherapy, 2007, 51, 3915-3923.	3.2	70
58	Engineering and Analysis of a Self-Sufficient Biosynthetic Cytochrome P450 PtkC Fused to the RhFRED Reductase Domain. Journal of the American Chemical Society, 2007, 129, 12940-12941.	13.7	102
59	Ligand-Assisted Inhibition in Cytochrome P450 158A2 from Streptomyces coelicolor A3(2)., Biochemistry, 2006, 45, 7493-7500.	2.5	4
60	A Second FMN Binding Site in Yeast NADPH-Cytochrome P450 Reductase Suggests a Mechanism of Electron Transfer by Diflavin Reductases. Structure, 2006, 14, 51-61.	3.3	57
61	The Structural Basis for Substrate Anchoring, Active Site Selectivity, and Product Formation by P450 PtkC from Streptomyces venezuelae. Journal of Biological Chemistry, 2006, 281, 26289-26297.	3.4	129
62	Binding of Two Flavinol Substrate Molecules, Oxidative Coupling, and Crystal Structure of Streptomyces coelicolor A3(2) Cytochrome P450 158A2. Journal of Biological Chemistry, 2005, 280, 11599-11607.	3.4	142
63	Expansion of Substrate Specificity of Cytochrome P450 2A6 by Random and Site-directed Mutagenesis*. Journal of Biological Chemistry, 2005, 280, 41090-41100.	3.4	65
64	Identification of Amino Acids in Rat Pregnane X Receptor that Determine Species-Specific Activation. Molecular Pharmacology, 2004, 65, 36-44.	2.3	76
65	Estriol Bound and Ligand-free Structures of Sterol 14 $\alpha$ -Demethylase. Structure, 2004, 12, 1937-1945.	3.3	78
66	Comparison of the 1.85 Å structure of CYP154A1 from Streptomyces coelicolor A3(2) with the closely related CYP154C1 and CYPs from antibiotic biosynthetic pathways. Protein Science, 2004, 13, 255-268.	7.6	50
67	The 1.92-Å... Structure of Streptomyces coelicolor A3(2) CYP154C1. Journal of Biological Chemistry, 2003, 278, 12214-12221.	3.4	76
68	The Cytochrome P450 Complement (CYPome) of Streptomyces coelicolor A3(2). Journal of Biological Chemistry, 2002, 277, 24000-24005.	3.4	117
69	Sterol 14 $\alpha$ -demethylase activity in Streptomyces coelicolor A3(2) is associated with an unusual member of the CYP51 gene family. Biochemical Journal, 2002, 364, 555-562.	3.7	24
70	Substrate recognition sites in 14 $\alpha$ -sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. Journal of Inorganic Biochemistry, 2001, 87, 227-235.	3.5	65
71	Folding Requirements Are Different between Sterol 14 $\alpha$ -Demethylase (CYP51) from Mycobacterium tuberculosis and Human or Fungal Orthologs. Journal of Biological Chemistry, 2001, 276, 28413-28420.	3.4	44
72	Crystal Structure of the CCAAT Box/Enhancer-binding Protein $\hat{1}^2$ Activating Transcription Factor-4 Basic Leucine Zipper Heterodimer in the Absence of DNA. Journal of Biological Chemistry, 2001, 276, 505-513.	3.4	83

#	ARTICLE	IF	CITATIONS
73	DNA polymerase $\delta$ holoenzyme: action on single-stranded DNA and on double-stranded DNA in the presence of replicative DNA helicases. <i>Biochemistry</i> , 1995, 34, 5003-5010.	2.5	52
74	Mechanism of Inhibition of Proliferating Cell Nuclear Antigen-Dependent DNA Synthesis by the Cyclin-Dependent Kinase Inhibitor p21. <i>Biochemistry</i> , 1995, 34, 8869-8875.	2.5	124
75	Assembly of DNA polymerase $\delta$ and $\epsilon$ holoenzymes depends on the geometry of the DNA template. <i>Nucleic Acids Research</i> , 1994, 22, 2970-2975.	14.5	57